Alnylam

Press Releases

Oct 02,2018
Summary ToggleAlnylam Launches ONPATTRO™ (patisiran), the First-Ever RNAi Therapeutic, in Germany
PDF Version
Oct 02,2018
Summary ToggleAlnylam Reports New Platform Innovations for RNAi Therapeutics at the Oligonucleotide Therapeutics Society 2018 Annual Meeting
PDF Version
Sep 28,2018
Summary ToggleAlnylam Announces Submission of New Drug Application in Japan for ONPATTRO™ (patisiran sodium) for Treatment of Hereditary ATTR Amyloidosis
PDF Version
Sep 27,2018
Summary ToggleAlnylam Announces Positive Topline Results from Interim Analysis of ENVISION Phase 3 Study of Givosiran in Patients with Acute Hepatic Porphyria
PDF Version
Sep 26,2018
Summary ToggleAlnylam to Webcast Presentation at the 2018 Cantor Global Healthcare Conference
PDF Version
Sep 24,2018
Summary ToggleAlnylam Pharmaceuticals Receives Priority Review in Canada for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Polyneuropathy
PDF Version
Sep 14,2018
Summary ToggleAlnylam Announces Publication in Circulation of Exploratory Cardiac Endpoint Data from APOLLO Phase 3 Study of Patisiran
PDF Version
Aug 30,2018
Summary ToggleAlnylam Receives Approval of ONPATTRO™ (patisiran) in Europe
PDF Version
Aug 29,2018
Summary ToggleAlnylam to Webcast Presentations at Upcoming September Investor Conferences
PDF Version
Aug 21,2018
Summary ToggleAlnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)
PDF Version
Aug 10,2018
Summary ToggleAlnylam Announces Alignment on Value-Based Agreements with Leading Health Insurers and Launches Comprehensive Patient Support Services for ONPATTRO™ (patisiran)
PDF Version
Aug 10,2018
Summary ToggleAlnylam Announces First-Ever FDA Approval of an RNAi Therapeutic, ONPATTRO™ (patisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
PDF Version
Aug 03,2018
Summary ToggleAlnylam Announces that the United Kingdom’s MHRA Grants Early Access to Patisiran
PDF Version
Aug 02,2018
Summary ToggleAlnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results and Highlights Recent Period Activity
PDF Version
Jul 27,2018
Summary ToggleAlnylam to Webcast Conference Call Discussing Second Quarter 2018 Financial Results
PDF Version
Jul 27,2018
Summary ToggleAlnylam Receives Positive CHMP Opinion for ONPATTRO™ (patisiran) for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults with Stage 1 or Stage 2 Polyneuropathy
PDF Version
Jul 23,2018
Summary ToggleAlnylam Presents New Analyses of Clinical Results from APOLLO Phase 3 Study of Patisiran at 2018 Peripheral Nerve Society Annual Meeting
PDF Version
Jul 04,2018
Summary ToggleAlnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine
PDF Version
Jun 21,2018
Summary ToggleAlnylam to Host Fifth Annual “RNAi Roundtable” Webcast Series
PDF Version
Jun 20,2018
Summary ToggleAlnylam Expands Senior Leadership Team with Two Key Appointments
PDF Version
Displaying 21 - 40 of 996 results
View all releases

Search

: (Common):

Price:
Change (%):
Volume:
Data as of
Copyright NASDAQ. Minimum 15 minutes delay
Learn More